Can immunotherapy shrink Betel-Nut oral tumors before surgery?
NCT ID NCT07733466
First seen Jul 29, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This trial tests whether giving two immunotherapy drugs—pembrolizumab and cetuximab—before surgery can shrink advanced oral cancers linked to betel-nut chewing. The study enrolls 20 people in the Northern Mariana Islands who have not yet received treatment. Researchers will measure tumor response using CT scans to see if the combination leads to partial or complete shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and cetuximab
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with betel-nut-related oral cancer.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The combination may cause immune-related side effects, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETEL-NUT-ASSOCIATED ORAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northern Marianas Oncology Center | Commonwealth Healthcare Corporation
Saipan, 96950, Northern Mariana Islands